Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as nonurothelial tract recurrence-free survival (NUTRFS), distant metastasis-free survival (DMFS), and second progression-free survival (PFS2). An exploratory analysis assessed outcomes in the muscle-invasive urothelial carcinoma (MIBC) subgroup, prior neoadjuvant chemotherapy (NAC) use, and PD-L1 expression. This analysis was conducted to further evaluate efficacy across subgroups and refine the understanding of treatment impact.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

Now Viewing

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

• Please review the updated results from CheckMate 274. (Galsky 2025)
• Updated DFS and interim OS
• Other end points (eg, NUTRFS, DMFS, PFS2)
• Exploratory analysis of MIBC subgroup, prior NAC, PD-L1 expression
• Why was this analysis performed?

Recent Videos